Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Scienture reports preliminary Q3 2026 revenue of $1.22 million, up sharply on Rezenopy launchOct 19Quarterly updatelosartannaloxone
Scienture launches REZENOPY, cites patent wins and payer gains in Q2 2026 updateAug 20Quarterly updatenaloxoneScienture Holdings, Inc.
Emergent BioSolutions posts Q2 revenue surge but takes $191 million impairment, cuts 2026 outlookAug 5Quarterly updateEmergent BioSolutions